Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-label, Phase Ib/II Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Subjects With Advanced Solid Tumors or AK104 in Combination With Oxaliplatin and Capecitabine As First-line Therapy in Subjects With Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Next Previous
Trial Profile

A Multicenter, Open-label, Phase Ib/II Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Subjects With Advanced Solid Tumors or AK104 in Combination With Oxaliplatin and Capecitabine As First-line Therapy in Subjects With Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cadonilimab (Primary) ; Capecitabine; Oxaliplatin
  • Indications Adenocarcinoma; Cervical cancer; Gastric cancer; Liver cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms COMPASSION-03
  • Sponsors Akeso Biopharma

Most Recent Events

  • 31 Jul 2024 Status changed from active, no longer recruiting to completed.
  • 01 Jul 2024 Primary endpoint (Anti-tumor activitiy of AK104 using objective response rate (ORR) based on RECIST v1.1 as assessed by the investigator (Phase II)) has been met, according to the results published in the Nature Medicine.
  • 01 Jul 2024 Results (n=98, data cut-off- 12 July 2023) assessing the safety and efficacy of Cadonilimab plus chemotherapy as first-line treatment in HER2 negative unresectable advanced or metastatic gastric or GEJ adenocarcinoma, published in the Nature Medicine

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top